NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free DRRX Stock Alerts $0.93 +0.01 (+1.17%) (As of 09:30 AM ET) Add Compare Share Share Today's Range$0.93▼$0.9350-Day Range$0.77▼$1.3752-Week Range$0.47▼$7.46Volume14,326 shsAverage Volume184,116 shsMarket Capitalization$28.76 millionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get DURECT alerts: Email Address DURECT MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside2,902.5% Upside$27.50 Price TargetShort InterestHealthy3.19% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.16 out of 5 starsMedical Sector244th out of 908 stocksPharmaceutical Preparations Industry102nd out of 425 stocks 3.3 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDURECT has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.19% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in DURECT has recently decreased by 9.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 3.6 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DURECT this week, compared to 1 article on an average week.Search Interest13 people have searched for DRRX on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat Follows8 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($1.04) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About DURECT Stock (NASDAQ:DRRX)DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More DRRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRRX Stock News HeadlinesApril 26, 2024 | americanbankingnews.comDURECT Co. (NASDAQ:DRRX) Given Average Recommendation of "Moderate Buy" by AnalystsApril 1, 2024 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call TranscriptApril 26, 2024 | Tranzact (Ad)What is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. March 27, 2024 | benzinga.comDurect: Q4 Earnings InsightsMarch 27, 2024 | markets.businessinsider.comDURECT Corp. Q4 Loss decreases, beats estimatesMarch 27, 2024 | finance.yahoo.comDURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 27, 2024March 27, 2024 | msn.comDURECT Q4 2023 Earnings PreviewApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 20, 2024 | finance.yahoo.comDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateMarch 20, 2024 | prnewswire.comDURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateMarch 16, 2024 | finance.yahoo.comDRRX Apr 2024 5.000 callMarch 16, 2024 | finance.yahoo.comDRRX Apr 2024 0.500 putMarch 4, 2024 | markets.businessinsider.comDURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product LineMarch 4, 2024 | msn.comDURECT and Charles River enter agreement for alzet in U.S., CanadaMarch 4, 2024 | finance.yahoo.comDURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and CanadaFebruary 24, 2024 | finance.yahoo.comDRRX Mar 2024 1.500 putFebruary 7, 2024 | finance.yahoo.comDURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 29, 2024 | msn.comEarth Science Tech to effect up to $5M stock repurchase programNovember 16, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Taysha Gene Therapies (TSHA) and Durect (DRRX)November 15, 2023 | seekingalpha.comDURECT: Reading Into AHFIRM Mortality RatesNovember 13, 2023 | benzinga.comRecap: Durect Q3 EarningsNovember 13, 2023 | finance.yahoo.comDURECT Corporation Reports Third Quarter 2023 Financial Results and Business UpdateNovember 12, 2023 | morningstar.comDurect Corp DRRXNovember 10, 2023 | benzinga.com4DRRX : Durect Earnings PreviewNovember 10, 2023 | msn.comJonesTrading Downgrades Durect (DRRX)November 9, 2023 | finance.yahoo.comDURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business UpdateSee More Headlines Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/26/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$27.50 High Stock Price Target$41.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,902.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,620,000.00 Net Margins-323.16% Pretax Margin-323.16% Return on Equity-316.78% Return on Assets-76.59% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.20 Sales & Book Value Annual Sales$8.55 million Price / Sales3.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book1.83Miscellaneous Outstanding Shares31,040,000Free Float29,701,000Market Cap$28.43 million OptionableOptionable Beta0.85 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. James E. Brown D.V.M. (Age 67)Co-Founder, CEO, President & Director Comp: $633.46kMr. Timothy M. Papp M.B.A. (Age 48)CFO & Secretary Comp: $427.62kDr. Norman L. Sussman M.D. (Age 71)Chief Medical Officer Comp: $471.71kMs. Judy R. Joice (Age 67)Senior Vice President of Operations & Corporate Quality Assurance Comp: $451.82kDr. WeiQi Lin M.D.Ph.D., Executive VP of Research & Development and Principal ScientistMr. Keith L. Lui M.B.A.Senior Vice President of Business Development, Commercial & Medical AffairsMs. Jian Li M.B.A. (Age 54)Senior VP of Finance, Corporate Controller & Secretary Comp: $297.08kDr. Su Il Yum Ph.D. (Age 85)Executive Officer Comp: $331.74kMore ExecutivesKey CompetitorsQilian International Holding GroupNASDAQ:QLIIterum TherapeuticsNASDAQ:ITRMEyenoviaNASDAQ:EYENSol-Gel TechnologiesNASDAQ:SLGLLipocineNASDAQ:LPCNView All CompetitorsInstitutional OwnershipRichmond Brothers Inc.Bought 518,294 shares on 2/8/2024Ownership: 1.737%View All Institutional Transactions DRRX Stock Analysis - Frequently Asked Questions Should I buy or sell DURECT stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DRRX shares. View DRRX analyst ratings or view top-rated stocks. What is DURECT's stock price target for 2024? 5 Wall Street analysts have issued twelve-month target prices for DURECT's stock. Their DRRX share price targets range from $5.00 to $41.00. On average, they anticipate the company's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 2,902.5% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts. How have DRRX shares performed in 2024? DURECT's stock was trading at $0.59 at the start of the year. Since then, DRRX shares have increased by 55.2% and is now trading at $0.9159. View the best growth stocks for 2024 here. Are investors shorting DURECT? DURECT saw a drop in short interest in April. As of April 15th, there was short interest totaling 927,500 shares, a drop of 10.0% from the March 31st total of 1,030,000 shares. Based on an average daily trading volume, of 169,000 shares, the days-to-cover ratio is presently 5.5 days. Approximately 3.2% of the company's stock are short sold. View DURECT's Short Interest. When is DURECT's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our DRRX earnings forecast. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) released its earnings results on Wednesday, March, 27th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.09. The specialty pharmaceutical company earned $2.67 million during the quarter, compared to analyst estimates of $2.70 million. DURECT had a negative trailing twelve-month return on equity of 316.78% and a negative net margin of 323.16%. When did DURECT's stock split? DURECT's stock reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRRX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
